Timil Patel
Yale University
21 Papers
35 Citations
Timil Patel is an academic researcher from Yale University. The author has contributed to research in topics: Medicine & Transplantation. The author has an hindex of 5, co-authored 17 publications. Previous affiliations of Timil Patel include Society of Hospital Medicine & University of Texas Southwestern Medical Center.
Chat about Author
Papers
Extracellular Matrix Scaffold Technology for Bioartificial Pancreas Engineering State of the Art and Future Challenges
Marcus Salvatori,Ravi Katari,Timil Patel,Andrea Peloso,Jon Mugweru,Kofi Owusu,Giuseppe Orlando +6 more
TL;DR: The native ECM has proven to be an optimal platform for recellularization and whole-organ pancreas bioengineering, an exciting new field with the potential to resolve the dire shortage of transplantable organs.
58
Impact of mtor-i on fertility and pregnancy: State of the art and review of the literature
Marialuisa Framarino-dei-Malatesta,Martina Derme,Tommaso Maria Manzia,Giuseppe Iaria,Linda De Luca,Laura Fazzolari,Angela Napoli,Pasquale Berloco,Timil Patel,Timil Patel,Giuseppe Orlando,Giuseppe Tisone +11 more
TL;DR: The aim of this study would be to review the impact of mTORi on fertility and pregnancy in order to have a clearer picture about their possible use after organ transplantation.
38
Margin negative resection and pathologic downstaging with multiagent chemotherapy with or without radiotherapy in patients with localized pancreas cancer: A national cancer database analysis.
Joseph A. Miccio,Wesley J. Talcott,Timil Patel,Henry S. Park,Michael Cecchini,Ronald R. Salem,Sajid A. Khan,Stacey Stein,Jeremy S. Kortmansky,Jill Lacy,Amol Narang,Joseph M. Herman,Salma K. Jabbour,Christopher L. Hallemeier,Kimberly L. Johung,Krishan R. Jethwa +15 more
TL;DR: This report studies neoadjuvant chemotherapy with or without radiation for pancreatic cancer and found the addition of radiation was associated with improved complete resection rates and improved pathologic down staging.
13
FDA Approval Summary: Pemigatinib for Previously Treated, Unresectable Locally Advanced or Metastatic Cholangiocarcinoma with FGFR2 fusion or other rearrangement.
Timil Patel,Leigh Marcus,M. N. Horiba,Martha Donoghue,Somak Chatterjee,Pallavi S. Mishra-Kalyani,Robert N. Schuck,Yangbing Li,Xinyuan Zhang,Jeanne Fourie Zirkelbach,Rosane Charlab,Jian Liu,Yuching Yang,Steven Lemery,Richard Pazdur,Marc R. Theoret,Lola Fashoyin-Aje +16 more
TL;DR: On April 17, 2020, the Food and Drug Administration granted accelerated approval to pemigatinib for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test.
12
Reliable prediction of survival in advanced-stage hepatocellular carcinoma treated with sorafenib: comparing 1D and 3D quantitative tumor response criteria on MRI
Luzie A. Doemel,Luzie A. Doemel,Julius Chapiro,Fabian Laage Gaupp,Lynn Jeanette Savic,Lynn Jeanette Savic,Ahmet S Kucukkaya,Ahmet S Kucukkaya,Alexandra Petukhova,Alexandra Petukhova,Jonathan Tefera,Jonathan Tefera,Tal Zeevi,MingDe Lin,Todd Schlachter,Ariel Jaffe,Mario Strazzabosco,Timil Patel,Stacey Stein +18 more
TL;DR: 3D quantitative tumor response criteria applied to DCE-MRI in patients with advanced-stage HCC undergoing sorafenib therapy to predict overall survival (OS) early during treatment provides evidence for potential advantages 3D quantitative, enhancement-based tumor response analysis over conventional techniques regarding early identification of treatment success or failure.
11